DA
SAGE

Duality Advisers’s Sage Therapeutics SAGE Stock Holding History

Duality Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,334
Closed -$624K – 706
2022
Q2 		$624K Sell
19,334
-10,339
-35% -$347K 0.06% 428
2022
Q1 		$982K Buy
+29,673
New +$1.12M 0.11% 322
2021
Q4 		– Sell
-10,641
Closed -$472K – 659
2021
Q3 		$472K Buy
+10,641
New +$488K 0.04% 451
2020
Q4 		– Sell
-21,590
Closed -$1.32M – 706
2020
Q3 		$1.32M Buy
+21,590
New +$1.09M 0.08% 308

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Duality Advisers's SAGE Position: Q3 2022 in Review

Duality Advisers sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 19,334 shares — an estimated $624K sold.

Duality Advisers first reported a position in SAGE in Q3 2020 and held it in 4 quarters. The position peaked at $1.32M in Q3 2020. 201 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • Duality Advisers reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Duality Advisers sold 19,334 Sage Therapeutics shares in Q3 2022, an estimated $624K.
  • Duality Advisers first reported a position in Sage Therapeutics in Q3 2020 and held it in 4 quarters.
  • Duality Advisers's Sage Therapeutics position peaked at $1.32M in Q3 2020.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Duality Advisers's 13F filing for Q3 2022, filed 3 Nov 2022.